AbbVie Inc. (ABBV)

Oncology Corporate Profile

Stock Performance

66.1000
0.0000

HQ Location

100 Abbott Park Rd.
North Chicago, IL 60064

Company Description

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries.

Website: http://www.abbvie.com

Brand Generic Indication
EMPLICITI_?elotuzumabEMPLICITI is a SLAMF7-directed immunostimulatory antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies
IMBRUVICA?? ibrutinibIMBRUVICA is a kinase inhibitor indicated for the treatment of patients with:



_??Mantle cell lymphoma (MCL) who have received at least one prior therapy.



Accelerated approval was granted for this indication based on overall response rate. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trials.



_??Chronic lymphocytic leukemia (CLL)



_??Chronic lymphocytic leukemia with 17p deletion.



_??Waldenstr?_m_?_s macroglobulinemia
VENCLEXTA_? venetoclaxVENCLEXTA is a BCL-2 inhibitor indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy.



This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

View additional information on commercial products here »

  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
elotuzumab (+ lenalidimide and dexamethasone) / Huluc63anti-CS1 monoclonal antibody (humanized)2nd line metastatic Multiple MyelomaIIIBristol-Myers Squibb
veliparib / ABT-888PARP inhibitorBRCA Breast cancerIII
veliparib / ABT-888PARP inhibitorNon Small Cell Lung Cancer (NSCLC)III
veliparib / ABT-888PARP inhibitorOvarian cancerIII
veliparib / ABT-888PARP inhibitorsquamous Non Small Cell Lung Cancer (NSCLC)III
veliparib / ABT-888PARP inhibitorTriple negative Breast cancer III
Empliciti / elotuzumabmonoclonal antibody1st line Multiple MyelomaIII
Imbruvica_ / ibrutinibBruton's tyrosine kinase (BTK) inhibitorDiffuse Large B-Cell Lymphoma (DLBCL)III
Imbruvica_ / ibrutinibBruton's tyrosine kinase (BTK) inhibitorFollicular Lymphoma (FL)III
Imbruvica_ / ibrutinibBruton's tyrosine kinase (BTK) inhibitorMultiple MyelomaIII
Imbruvica_ / ibrutinibBruton's tyrosine kinase (BTK) inhibitorPancreatic cancerIII
Venclexta / ABT-199Bcl-2 inhibitor1st line Chronic Lymphocytic Leukemia (CLL)III
Venclexta / ABT-199Bcl-2 inhibitorAcute Myelogenous Leukemia (AML)III
Venclexta / ABT-199Bcl-2 inhibitorMultiple MyelomaIII
Venclexta / ABT-199Bcl-2 inhibitorRelapsed refractory Chronic Lymphocytic Leukemia (CLL)III
Imbruvica_ / ibrutinibBruton's tyrosine kinase (BTK) inhibitorAcute Myelogenous Leukemia (AML)II
Imbruvica_ / ibrutinibBruton's tyrosine kinase (BTK) inhibitorVarious cancer typesII
Rova-T / rovalpituzumab tesirine (+nivolumab and ipilimumab)antibody drug conjugateSmall Cell Lung Cancer (SCLC)IIBristol-Myers Squibb
Venclexta / ABT-199Bcl-2 inhibitorDiffuse Large B-Cell Lymphoma (DLBCL)II
Venclexta / ABT-199Bcl-2 inhibitorFollicular Lymphoma (FL)II
ABBV-075small molecule Bromodomain and Extra-Terminal motif (BET) inhibitorAcute Myelogenous Leukemia (AML)I
ABBV-075small molecule Bromodomain and Extra-Terminal motif (BET) inhibitorMultiple MyelomaI
ABBV-838antibody drug conjugateMultiple MyelomaI
ABBV-075small molecule Bromodomain and Extra-Terminal motif (BET) inhibitorVarious cancer typesI
ABBV-085antibody drug conjugateVarious cancer typesI
ABBV-339antibody drug conjugateVarious cancer typesI
ABBV-221antibody drug conjugateVarious cancer typesI
ABT-165Dual variable domain immunoglobulin (DVD)Various cancer typesI
Rova-T / rovalpituzumab tesirineantibody drug conjugateNeuroendocrine tumorI

View additional information on product candidates here »

Source


http://www.abbvie.com

Recent News Headlines

Shire: Can It Pay Down Debt?

3/27/2017 05:03 pm

Julianne Hough Empowers Women to "Get in the Know" About Endometriosis

3/23/2017 11:04 am

[PR Newswire] - NORTH CHICAGO, Ill., March 23, 2017 /PRNewswire/ -- AbbVie, a global biopharmaceutical company, today announced that actress, dancer and Emmy Award-winning choreographer Julianne Hough is helping to raise awareness about endometriosis through a campaign called "Get in the Know about ME in EndoMEtriosis." The campaign, sponsored by AbbVie, is dedicated to inspiring women to learn about and understand endometriosis, a disease affecting an estimated one in 10 women,1 and to address their symptoms with a healthcare professional. Despite being one of the most common gynecologic disorders in America, there is a lack of awareness and prioritization of endometriosis as an important women's health issue.

Blog Coverage Eli Lilly Announced Positive Results from Breast Cancer Drug Combination Study

3/22/2017 12:01 pm

[Accesswire] - Upcoming AWS Coverage on AbbVie LONDON, UK / ACCESSWIRE / March 22, 2017 / Active Wall St. blog coverage looks at the headline from US drugmaker Eli Lilly and Co. (NYSE: LLY ) as the Company announced ...

Update in Lawsuit for Investors in NYSE: ABBV Shares Against AbbVie Inc. Announced by Shareholders Foundation

3/20/2017 01:03 pm

[Accesswire] - SAN DIEGO, CA / ACCESSWIRE / March 20, 2017 / The Shareholders Foundation, Inc. announces that a lawsuit is pending in Illinois on behalf of certain purchasers of (NYSE: ABBV) shares over alleged Securities ...

AbbVie Granted Priority Review in Japan for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C

3/14/2017 12:00 pm

[PR Newswire] - NORTH CHICAGO, Ill., March 14, 2017 /PRNewswire/ -- AbbVie (ABBV), a global biopharmaceutical company, today announced that priority review has been granted by the Japanese Ministry of Health, Labour and Welfare (MHLW) for its investigational, pan-genotypic, ribavirin-free regimen of glecaprevir/pibrentasvir (G/P) for the treatment of all major genotypes (GT1-6) of the chronic hepatitis C virus (HCV). This priority review follows European Medicines Agency (EMA) accelerated assessment and U.S. Food and Drug Administration (FDA) priority review designations in December 2016 and January 2017 respectively.